| Literature DB >> 25495840 |
Yin Bun Cheung, Nan Luo, Raymond Ng, Chun Fan Lee1.
Abstract
PURPOSE: To develop an algorithm for mapping the Functional Assessment of Cancer Therapy-Breast (FACT-B) to the 5-level EuroQoL Group's 5-dimension questionnaire (EQ-5D-5L) utility index.Entities:
Mesh:
Year: 2014 PMID: 25495840 PMCID: PMC4267156 DOI: 10.1186/s12955-014-0180-6
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Demographic and baseline information of 238 eligible subjects
|
|
|
|
|---|---|---|
| Age (year), Mean (standard deviation) | 51.3 | (9.7) |
| Language of questionnaire | ||
| English | 160 | (67.2) |
| Chinese | 78 | (32.8) |
| Race | ||
| Chinese | 193 | (81.1) |
| Malay | 23 | (9.7) |
| Indian | 18 | (7.6) |
| Others | 4 | (1.7) |
| Marital status | ||
| Married | 168 | (70.9) |
| Single | 47 | (19.8) |
| Divorced/separated | 12 | (5.1) |
| Widowed | 10 | (4.2) |
| Education level | ||
| Primary or below | 48 | (20.3) |
| Secondary | 112 | (47.3) |
| Postsecondary | 77 | (32.5) |
| Inpatient/Outpatient | ||
| Inpatient | 70 | (29.4) |
| Outpatient | 168 | (70.6) |
| Patient-assessed performance status | ||
| 0 | 97 | (40.8) |
| 1 | 115 | (48.3) |
| 2 | 17 | (7.1) |
| 3 or 4 | 9 | (3.8) |
| Evidence of disease | ||
| Present | 118 | (50.0) |
| Absent | 118 | (50.0) |
| Purpose of visit | ||
| Treatment – Adjuvant/curative/hormone therapy | 112 | (47.7) |
| Treatment – Palliative | 78 | (33.2) |
| No treatment – Follow-up | 45 | (19.1) |
| On chemotherapy/radiotherapy | ||
| Yes | 100 | (42.0) |
| No | 138 | (58.0) |
Distribution of EQ-5D-5L and FACT-B scores and subscales at baseline and follow-up
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| EQ-5D-5L utility index | |||||||||
| Japanese value set | 0.777 | 0.163 | 0.179 | 0.686 | 0.740 | 0.843 | 1.000 | 0 (0.0%) | 59 (24.8%) |
| UK value set | 0.785 | 0.200 | −0.283 | 0.721 | 0.777 | 0.906 | 1.000 | 0 (0.0%) | 59 (24.8%) |
| FACT-B | |||||||||
| Total score | 103.0 | 20.8 | 45 | 90 | 104 | 119 | 140 | 0 (0.0%) | 0 (0.0%) |
| FACT-G score | 81.3 | 16.9 | 35 | 71 | 83 | 95 | 108 | 0 (0.0%) | 4 (1.7%) |
| Trial outcome index | 62.8 | 14.9 | 16 | 53 | 64 | 74 | 89 | 0 (0.0%) | 0 (0.0%) |
| Physical well-being | 21.1 | 6.0 | 1 | 18 | 22 | 26 | 28 | 0 (0.0%) | 29 (12.2%) |
| Social well-being | 22.2 | 6.1 | 0 | 20 | 24 | 27 | 28 | 3 (1.3%) | 50 (21.0%) |
| Emotional well-being | 18.0 | 4.7 | 4 | 15 | 19 | 22 | 24 | 0 (0.0%) | 28 (11.8%) |
| Functional well-being | 20.0 | 6.7 | 0 | 16 | 21 | 26 | 28 | 3 (1.3%) | 31 (13.0%) |
| Breast cancer subscale | 21.7 | 6.1 | 5 | 17 | 22 | 27 | 36 | 0 (0.0%) | 1 (0.4%) |
|
| |||||||||
| EQ-5D-5L utility index | |||||||||
| Japanese value set | 0.758 | 0.160 | 0.052 | 0.649 | 0.740 | 0.829 | 1.000 | 0 (0.0%) | 46 (20.8%) |
| UK value set | 0.770 | 0.193 | −0.283 | 0.679 | 0.768 | 0.879 | 1.000 | 0 (0.0%) | 46 (20.8%) |
| FACT-B | |||||||||
| Total score | 101.2 | 22.2 | 27 | 85 | 103 | 118 | 140 | 0 (0.0%) | 0 (0.0%) |
| FACT-G score | 79.6 | 18.0 | 20 | 67 | 82 | 94 | 108 | 0 (0.0%) | 5 (2.3%) |
| Trial outcome index | 61.6 | 15.8 | 9 | 51 | 63 | 74 | 89 | 0 (0.0%) | 0 (0.0%) |
| Physical well-being | 21.0 | 6.1 | 0 | 17 | 22 | 26 | 28 | 2 (0.9%) | 26 (11.8%) |
| Social well-being | 21.7 | 5.5 | 4 | 18 | 22 | 27 | 28 | 0 (0.0%) | 40 (18.1%) |
| Emotional well-being | 17.9 | 4.7 | 3 | 15 | 19 | 21 | 24 | 0 (0.0%) | 25 (11.3%) |
| Functional well-being | 19.0 | 6.9 | 2 | 14 | 21 | 25 | 28 | 0 (0.0%) | 20 (9.0%) |
| Breast cancer subscale | 21.6 | 6.2 | 7 | 17 | 22 | 26 | 35 | 0 (0.0%) | 0 (0.0%) |
Abbreviations: SD standard deviation, Min minimum, Q1 1st quartile, Q3 third quartile, Max maximum.
Coefficient estimates and goodness-of-fit measures of various regression models mapping the FACT-B subscales to EQ-5D-5L utility index based on baseline survey (N = 238)
|
|
|
|
|
| |
|---|---|---|---|---|---|
|
| |||||
|
| |||||
| Constant | 0.2901** | 0.3071** | 0.3064** | 0.2846** | 0.3031** |
| Physical well-being | 0.0120** | 0.0127** | 0.0125** | 0.0121** | 0.0128** |
| Social well-being | −0.0003 | −0.0003 | |||
| Emotional well-being | 0.0042* | 0.0062** | 0.0041 | 0.0061** | |
| Functional well-being | 0.0046** | 0.0048** | 0.0052** | 0.0044** | 0.0046** |
| Breast cancer subscale | 0.0035* | 0.0048** | 0.0034* | ||
|
| |||||
| Square of correlation coefficient, | 0.4975 | 0.4870 | 0.4890 | 0.4973 | 0.4870 |
| Adjusted | 0.4867 | 0.4782 | 0.4824 | 0.4887 | 0.4804 |
| Mean square error | 0.0132 | 0.0135 | 0.0135 | 0.0132 | 0.0135 |
| Mean absolute deviation | 0.0913 | 0.0918 | 0.0925 | 0.0913 | 0.0919 |
|
| |||||
|
| |||||
| Constant | 0.1983** | 0.2200** | 0.2342** | 0.2077** | 0.2318** |
| Physical well-being | 0.0144** | 0.0153** | 0.0147** | 0.0142** | 0.0152** |
| Social well-being | 0.0006 | 0.0007 | |||
| Emotional well-being | 0.0050 | 0.0077** | 0.0051 | 0.0078** | |
| Functional well-being | 0.0048* | 0.0051** | 0.0060** | 0.0051** | 0.0054** |
| Breast cancer subscale | 0.0045* | 0.0063** | 0.0046* | ||
|
| |||||
| Square of correlation coefficient, | 0.4965 | 0.4861 | 0.4887 | 0.4971 | 0.4869 |
| Adjusted | 0.4856 | 0.4773 | 0.4821 | 0.4885 | 0.4803 |
| Mean square error | 0.0143 | 0.0146 | 0.0145 | 0.0143 | 0.0145 |
| Mean absolute deviation | 0.0934 | 0.0937 | 0.0945 | 0.0934 | 0.0936 |
|
| |||||
|
| |||||
| Constant | 0.3062** | 0.3208** | 0.3200** | 0.2948** | 0.3149** |
| Physical well-being | 0.0119** | 0.0121** | 0.0123** | 0.0122** | 0.0121** |
| Social well-being | −0.0004 | −0.0003 | |||
| Emotional well-being | 0.0041 | 0.0054** | 0.0042 | 0.0054** | |
| Functional well-being | 0.0037* | 0.0054** | 0.0039* | 0.0037* | 0.0053** |
| Breast cancer subscale | 0.0036 | 0.0054** | 0.0035 | ||
|
| |||||
| Square of correlation coefficient, | 0.4968 | 0.4863 | 0.4873 | 0.4968 | 0.4862 |
| Adjusted | 0.4860 | 0.4775 | 0.4807 | 0.4882 | 0.4796 |
| Mean square error | 0.0133 | 0.0135 | 0.0135 | 0.0133 | 0.0135 |
| Mean absolute deviation | 0.0912 | 0.0917 | 0.0923 | 0.0913 | 0.0917 |
|
|
|
|
|
| |
|
| |||||
|
| |||||
| Constant | 0.3062** | 0.3208** | 0.3200** | 0.2948** | 0.3149** |
| Physical well-being | 0.0119** | 0.0121** | 0.0123** | 0.0122** | 0.0121** |
| Social well-being | −0.0004 | −0.0003 | |||
| Emotional well-being | 0.0041 | 0.0054** | 0.0042* | 0.0054** | |
| Functional well-being | 0.0037** | 0.0054** | 0.0039** | 0.0037** | 0.0053** |
| Breast cancer subscale | 0.0036 | 0.0054** | 0.0035 | ||
|
| |||||
| Square of correlation coefficient, | 0.4968 | 0.4863 | 0.4873 | 0.4968 | 0.4862 |
| Adjusted | 0.4860 | 0.4775 | 0.4807 | 0.4882 | 0.4796 |
| Mean square error | 0.0133 | 0.0135 | 0.0135 | 0.0133 | 0.0135 |
| Mean absolute deviation | 0.0912 | 0.0917 | 0.0923 | 0.0913 | 0.0917 |
|
| |||||
|
| |||||
| Constant | −1.6525 | −1.6097 | −1.5750* | −1.6489 | −1.6678 |
| Physical well-being | 0.0684 | 0.0710 | 0.0678* | 0.0683** | 0.0722** |
| Social well-being | 0.0001 | −0.0035 | |||
| Emotional well-being | 0.0155 | 0.0320 | 0.0157 | 0.0308 | |
| Functional well-being | 0.0230 | 0.0312 | 0.0247 | 0.0230 | 0.0295 |
| Breast cancer subscale | 0.0216 | 0.0301 | 0.0214 | ||
|
| |||||
| Square of correlation coefficient, | 0.4686 | 0.4596 | 0.4620 | 0.4687 | 0.4597 |
| Adjusted | 0.4571 | 0.4503 | 0.4551 | 0.4596 | 0.4528 |
| Mean square error | 0.0141 | 0.0143 | 0.0143 | 0.0141 | 0.0143 |
| Mean absolute deviation | 0.0946 | 0.0949 | 0.0953 | 0.0946 | 0.0950 |
**P-value < 0.01; *P-value < 0.05.
Descriptive summary of the baseline EQ-5D-5L utility index derived from observed data and regression models
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| Observed data | 0.7772 | 0.1626 | 0.1789 | 0.6079 | 0.6856 | 0.7402 | 0.8428 | 1.0000 | 1.0000 | 24.8% |
|
| ||||||||||
| Model 3 | 0.7772 | 0.1137 | 0.3930 | 0.6162 | 0.7059 | 0.7902 | 0.8643 | 0.9150 | 0.9583 | 0% |
| Model 4 | 0.7772 | 0.1147 | 0.3830 | 0.6149 | 0.7082 | 0.7898 | 0.8648 | 0.9146 | 0.9498 | 0% |
| Model 5 | 0.7772 | 0.1135 | 0.3868 | 0.6211 | 0.7100 | 0.7891 | 0.8660 | 0.9138 | 0.9394 | 0% |
|
| ||||||||||
| Model 3 | 0.8005 | 0.1361 | 0.3414 | 0.6101 | 0.7127 | 0.8185 | 0.9032 | 0.9659 | 1.0203 | 2.5% |
| Model 4 | 0.8004 | 0.1372 | 0.3292 | 0.6057 | 0.7165 | 0.8153 | 0.9059 | 0.9653 | 1.0092 | 2.9% |
| Model 5 | 0.8004 | 0.1355 | 0.3341 | 0.6126 | 0.7224 | 0.8158 | 0.9059 | 0.9635 | 0.9949 | 0% |
|
| ||||||||||
| Model 3 | 0.7761 | 0.1095 | 0.4044 | 0.6274 | 0.7102 | 0.7887 | 0.8573 | 0.9094 | 0.9531 | 0% |
| Model 4 | 0.7760 | 0.1119 | 0.3896 | 0.6188 | 0.7119 | 0.7879 | 0.8609 | 0.9099 | 0.9448 | 0% |
| Model 5 | 0.7743 | 0.1107 | 0.3965 | 0.6183 | 0.7070 | 0.7870 | 0.8602 | 0.9083 | 0.9326 | 0% |
|
| ||||||||||
| Model 3 | 0.7761 | 0.1095 | 0.4044 | 0.6274 | 0.7102 | 0.7887 | 0.8573 | 0.9094 | 0.9531 | 0% |
| Model 4 | 0.7760 | 0.1119 | 0.3896 | 0.6188 | 0.7119 | 0.7879 | 0.8609 | 0.9099 | 0.9448 | 0% |
| Model 5 | 0.7743 | 0.1107 | 0.3965 | 0.6183 | 0.7070 | 0.7870 | 0.8602 | 0.9083 | 0.9326 | 0% |
|
| ||||||||||
| Model 3 | 0.7691 | 0.1042 | 0.3861 | 0.6221 | 0.7141 | 0.7936 | 0.8469 | 0.8804 | 0.9038 | 0% |
| Model 4 | 0.7680 | 0.1051 | 0.3780 | 0.6153 | 0.7146 | 0.7896 | 0.8463 | 0.8799 | 0.8971 | 0% |
| Model 5 | 0.7675 | 0.1085 | 0.3687 | 0.6093 | 0.7104 | 0.7914 | 0.8506 | 0.8817 | 0.8957 | 0% |
Abbreviations: SD standard deviation, Min minimum, P10 10th percentile, Q1 1st quartile, Q3 third quartile, P90 90th percentile, Max maximum.
Mean EQ-5D-5L utility index by patients’ self-assessed performance status at follow-up
|
|
| ||||
|---|---|---|---|---|---|
|
|
|
|
|
| |
| Observed data | 0.8719 | 0.7273 | 0.5941 | 0.5941 | |
|
| |||||
| Model 3 | 0.8518 | 0.7584** | 0.6499 | 0.5886 | < 0.001 |
| Model 4 | 0.8537 | 0.7581** | 0.6518 | 0.5883 | < 0.001 |
| Model 5 | 0.8560 | 0.7571** | 0.6495 | 0.5842 | < 0.001 |
|
| |||||
| Model 3 | 0.8890 | 0.7784** | 0.6498 | 0.5772 | < 0.001 |
| Model 4 | 0.8913 | 0.7780** | 0.6520 | 0.5768 | < 0.001 |
| Model 5 | 0.8944 | 0.7766** | 0.6490 | 0.5710 | < 0.001 |
|
| |||||
| Model 3 | 0.8478* | 0.7590** | 0.6558 | 0.6004 | < 0.001 |
| Model 4 | 0.8512 | 0.7580** | 0.6545 | 0.5948 | < 0.001 |
| Model 5 | 0.8505 | 0.7541** | 0.6487 | 0.5829 | < 0.001 |
|
| |||||
| Model 3 | 0.8478* | 0.7590** | 0.6558 | 0.6004 | < 0.001 |
| Model 4 | 0.8512 | 0.7580** | 0.6545 | 0.5948 | < 0.001 |
| Model 5 | 0.8505 | 0.7541** | 0.6487 | 0.5829 | < 0.001 |
|
| |||||
| Model 3 | 0.8341** | 0.7548** | 0.6526 | 0.5920 | < 0.001 |
| Model 4 | 0.8349** | 0.7532** | 0.6507 | 0.5886 | < 0.001 |
| Model 5 | 0.8387** | 0.7508** | 0.6422 | 0.5733 | < 0.001 |
aCuzick’s nonparametric test for trend [29].
**P-value < 0.01; *P-value < 0.05 for signed-rank test between observed and predicted utility index within the same performance status level.